Abstract

Understanding drug–drug interactions is an essential step to reduce the risk of adverse drug events before clinical drug co-prescription. Existing methods, commonly integrating heterogeneous data to increase model performance, often suffer from a high model complexity, As such, how to elucidate the molecular mechanisms underlying drug–drug interactions while preserving rational biological interpretability is a challenging task in computational modeling for drug discovery. In this study, we attempt to investigate drug–drug interactions via the associations between genes that two drugs target. For this purpose, we propose a simple f drug target profile representation to depict drugs and drug pairs, from which an l2-regularized logistic regression model is built to predict drug–drug interactions. Furthermore, we define several statistical metrics in the context of human protein–protein interaction networks and signaling pathways to measure the interaction intensity, interaction efficacy and action range between two drugs. Large-scale empirical studies including both cross validation and independent test show that the proposed drug target profiles-based machine learning framework outperforms existing data integration-based methods. The proposed statistical metrics show that two drugs easily interact in the cases that they target common genes; or their target genes connect via short paths in protein–protein interaction networks; or their target genes are located at signaling pathways that have cross-talks. The unravelled mechanisms could provide biological insights into potential adverse drug reactions of co-prescribed drugs.

Highlights

  • Understanding drug–drug interactions is an essential step to reduce the risk of adverse drug events before clinical drug co-prescription

  • We further propose several statistical metrics based on protein–protein interaction networks and signaling pathways to measure the intensity that drugs act on each other

  • The metrics of SP, SE and Matthews correlation coefficient (MCC) on the two classes show that the proposed framework is less biased, e.g., 0.9556 on the positive class, 0.9402 on the negative class in terms of sensitivity and 0.9007 overall MMC

Read more

Summary

Introduction

Understanding drug–drug interactions is an essential step to reduce the risk of adverse drug events before clinical drug co-prescription. We attempt to simplify the computational modeling for drug–drug interaction prediction on the basis of potential drug perturbations on associated genes and signaling pathways. The independent test performance shows that the proposed framework trained using drug target profile generalizes well to unseen drug–drug interactions with less bias.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.